Trials / Completed
CompletedNCT00379951
A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)
A Prospective, Multicenter, Noncomparative, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ertapenem sodium | ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days. |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2006-09-25
- Last updated
- 2017-02-17
Source: ClinicalTrials.gov record NCT00379951. Inclusion in this directory is not an endorsement.